CombiMatrix and Manhattan Labs enter into strategic partnerships

CombiMatrix and Manhattan Labs jointly announced that they have entered into a strategic partnership under which Manhattan Labs will market and distribute CombiMatrix microarray tests for the miscarriage management testing market in the New York City metropolitan area. The partnership was enabled by the announcement in late June that CombiMatrix miscarriage management tests had received conditional approval from the New York State Department of Health for testing on patient samples within the state. Manhattan Labs is a high-end, independent clinical laboratory that serves the New York City metropolitan area. Women's health, particularly obstetrics and reproductive issues, is one of Manhattan Lab's specialties, noted CEO Ken Cerney.